Regarding CTLA4, it is well known that it is the second target of checkpoint inhibition therapeutic approaches in RCC, and CTLA4 expression was significantly correlated with metastatic diseases and associated with a reduced survival in ccRCC [36]. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.